Clinical Trial Update: Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic Cardiomyopathy [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the effects of ranolazine on coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy (non-obstructive).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: IRCCS San Raffaele | Conditions: HCM - Hypertrophic Non-Obstructive Cardiomyopathy | Phase 2 | Status: COMPLETED